1. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Europ J Clin Microbiol Infect Dis. 2020;39:1011-9.
2. Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, et al. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses. 2022;14(7).
3. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-15.
4. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell. 2020;181(4):894-904.e9.
5. Siracusano G, Pastori C, Lopalco L. Humoral immune responses in COVID-19 patients: a window on the state of the art. Front Immunol. 2020;11:1049.
6. Hajilooi M, Keramat F, Moazenian A, Rastegari-Pouyani M, Solgi G. The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity. Med Microbiol Immunol. 2023;212(3):203-20.
7. Manuylov V, Burgasova O, Borisova O, Smetanina S, Vasina D, Grigoriev I, et al. Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection. Viruses. 2022;14(3).
8. Bauer G. The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity). J Med Virol. 2021;93(1):311-22.
9. Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol. 2012;30:429-57.
10. Young C, Brink R. The unique biology of germinal center
B cells. Immunity. 2021;54(8):1652-64.
11. Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, Hogan JJ, et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med. 2010;207(2):353-63.
12. Vijayan D, Mohd Redzwan N, Avery DT, Wirasinha RC, Brink R, Walters G, et al. IL-27 Directly Enhances Germinal Center B Cell Activity and Potentiates Lupus in Sanroque Mice. J Immunol. 2016;197(8):3008-17.
13. Löfström E, Eringfält A, Kötz A, Wickbom F, Tham J, Lingman M, et al. Dynamics of IgG-avidity and antibody levels after Covid-19. J Clin Virol. 2021;144:104986.
14. Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021;106:61-4.
15. Ding YX, Mao NY, Zhang Y, Lei Y, Gao ZG, Xu WB, et al. Measles Virus IgG Avidity Assay for Use in Identification of Measles Vaccine Failures in Tianjin, China. Biomed Environ Sci. 2019;32(11):804-11.
16. Acet Öztürk NA, Ursavaş A, Dilektaşlı AG, Demirdöğen E, Coşkun NF, Ediger D, et al. Interleukin-21: a potential biomarker for diagnosis and predicting prognosis in COVID-19 patients. Turk J Med Sci. 2021;51(5):2274-84.
17. Bayraktar N, Turan H, Bayraktar M, Ozturk A, Erdoğdu H. Analysis of serum cytokine and protective vitamin D levels in severe cases of COVID‐19. J Med Virol. 2022;94(1):154-60.
18. Tamayo-Velasco Á, Martínez-Paz P, Peñarrubia-Ponce MJ, de la Fuente I, Pérez-González S, Fernández I, et al. HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. J Clin Med. 2021;10(9).
19. Klingler J, Lambert GS, Bandres JC, Emami-Gorizi R, Nádas A, Oguntuyo KY, et al. Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients. iScience. 2022;25(12):105608.